Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Eric G. Vajda"'
Autor:
Eric G. Vajda, Juan P. Frias, Julio Rosenstock, James D. Pipkin, Jeremy Pettus, David A. D'Alessio, Miriam A. Zangmeister, Lin Zhi, Keith B. Marschke, Gretchen Williamson
Publikováno v:
Diabetes Care. 43:161-168
OBJECTIVE Evaluate the safety and efficacy of RVT-1502, a novel oral glucagon receptor antagonist, in subjects with type 2 diabetes inadequately controlled on metformin. RESEARCH DESIGN AND METHODS In a phase 2, double-blind, randomized, placebo-cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::232193507e0896aa524e75ac2e846b2d
https://doi.org/10.2337/dc19-1328
https://doi.org/10.2337/dc19-1328
Autor:
Diane J. Plotkin, Stacy C. Dilzer, Eric G. Vajda, Yong-Xi Li, Kenneth C. Lasseter, Xiaoxiong Wei, Keith B. Marschke, David Klein, Lin Zhi, Rong Zhou, Douglas Logan, James D. Pipkin, Danielle Armas
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD-6972, in healthy subjects and subjects with type 2 diabetes (T2DM). Methods In the single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb25b35b226814439e82f99f29b22ccb
http://europepmc.org/articles/PMC5215471
http://europepmc.org/articles/PMC5215471
Publikováno v:
Diabetes. 67
Glucagon receptor antagonists (GRA) are novel molecules in development for the treatment of type 1 and type 2 (T2DM) diabetes. LGD-6972 recently demonstrated robust efficacy in a 12-week, Phase 2 study in T2DM, reducing HbA1c by 1.2% from baseline, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22f5c95c01a48d6a1cb634d21f6d7135
https://doi.org/10.2337/db18-1117-p
https://doi.org/10.2337/db18-1117-p
Publikováno v:
Journal of Clinical Lipidology. 12:564-565
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9996e19842cb33e5730a5936f7574fc9
https://doi.org/10.1016/j.jacl.2018.03.070
https://doi.org/10.1016/j.jacl.2018.03.070
Autor:
Aimee Hogue, Eric G. Vajda, Francisco J. López, Dale E. Mais, Kelven Burnett, Keith B. Marschke, Lin Zhi, Arjan van Oeveren, Bijan Pedram, Yixing Shen, Yanling Chen, William Y. Chang, Kimberly N Griffiths, Martin D. Meglasson
Publikováno v:
Journal of Bone and Mineral Research. 24:231-240
Recent clinical trials with bisphosphonates and PTH have not supported the hypothesis that combination treatments with antiresorptive and anabolic agents would lead to synergistic activity. We hypothesized that combination treatment with a selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11520d3ccf194ce9a6e25dafa0fe1f01
https://doi.org/10.1359/jbmr.081007
https://doi.org/10.1359/jbmr.081007
Autor:
Eric G. Vajda, Rob Hill, Kyoung-Jin Lee, Francisco J. López, Martin D. Meglasson, Yong-Hee Lee, William Y. Chang, Zhihong O'Brien, Yanling Chen, Peter J. Rix
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 328:663-670
Selective androgen receptor modulators (SARMs) are a new class of molecules in development to treat a variety of diseases. SARMs maintain the beneficial effects of androgens, including increased muscle mass and bone density, while having reduced acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e46cdbf91aa764f39e0d32fc2be531
https://doi.org/10.1124/jpet.108.146811
https://doi.org/10.1124/jpet.108.146811
Autor:
Esther Martinborough, and Andrés Negro-Vilar, Keith B. Marschke, Thomas Lau, William Y. Chang, Yixing Shen, Francisco J. López, O. Humberto Viveros, Peter J. Rix, Eric G. Vajda, Arjan van Oeveren, Yun Oliver Long, Lin Zhi
Publikováno v:
Journal of medicinal chemistry. 50(21)
The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41b3a007cbb7644aace7d9a6250ceb4a
https://pubmed.ncbi.nlm.nih.gov/17887661
https://pubmed.ncbi.nlm.nih.gov/17887661
Publikováno v:
Cancer Research. 75:785-785
Signaling mediated by interleukin receptor associated kinase 4 (IRAK4) may play a permissive role in certain B-cell lymphomas. In addition, activating mutations of MYD88, which is upstream of IRAK4, have been identified in various B cell malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c4dfd388ad322dee1cf7f1db837c741
https://doi.org/10.1158/1538-7445.am2015-785
https://doi.org/10.1158/1538-7445.am2015-785
Publikováno v:
Anatomical Record; Sep2005, Vol. 286 Issue 1, p781-803, 23p